(firstQuint)A Study for Participants With Metastatic Renal Cell Carcinoma.

 This is a multicenter, Phase 2 study of enzastaurin and sunitinib versus placebo and sunitinib as first-line therapy in participants with metastatic renal cell carcinoma, containing 2 parts.

 Part 1 is a safety lead-in study with 12 participants and possible dose escalation.

 Part 2 is a randomized, double-blind, Phase 2 study in 110 participants.

.

 A Study for Participants With Metastatic Renal Cell Carcinoma@highlight

This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.

